Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization

详细信息    查看全文

• 作者：Katherine Y. Fan ; M.D.^a ; Aaron T. Wild ; M.D.^a ; Vivek G. Halappa ; M.D.^b ; Rachit Kumar ; M.D.^a ; Susannah Ellsworth ; M.D.^a ; Mark Ziegler ; B.S.^a ; Tanu Garg ; B.B.A.^a ; Lauren M. Rosati ; B.S.^a ; Zheng Su ; Ph.D.^c ; ^d ; Amy Hacker-Prietz ; MS ; PA-C^a ; Timothy M. Pawlik ; M.D. M.P.H. ; Ph.D.^e ; David P. Cosgrove ; M.D.^f ; Kelvin K. Hong ; M.B.B.Ch. ; M.B.B.S.^b ; Ihab R. Kamel ; M.D. ; Ph. D.^b ; Jean-Francois Geschwind ; M.D.^b ; ¹ ; ^{jfg@jhmi.edu" class="auth_mail" title="E-mail the corresponding author} ; Joseph M. Herman ; M.D. ; M.Sc^a ; ¹
• 关键词：Radioembolization ; Microsphere ; Yttrium-90 ; Neuroendocrine tumor ; Liver metastasis ; Unresectable
• 刊名：Contemporary Clinical Trials
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：50
• 期：Complete
• 页码：143-149
• 全文大小：324 K

文摘

Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic factors for radiographic response and survival.

Methods and materials

Thirty-eight patients underwent Y-90 radioembolization for NELM at our institution between April 2004 and February 2012. Patients were assessed radiographically (RECIST criteria, enhancement), serologically, and clinically at 1 month, and then at every 3 months after treatment for tumor response, toxicity, and survival outcomes.

Results

Median length of follow-up was 17.0 months (IQR, 9.0–37.0). Median survival was 29.2 months. Three patients (9%) had a radiographic complete response to treatment, 6 (17%) had a partial response, 21 (60%) had stable disease, and 5 (14%) developed progressive disease. Two factors were significantly associated with a good radiographic response (complete/partial response): islet cell histological subtype (p = 0.043) and hepatic tumor burden ≥ 33% (p = 0.031). Multivariate analysis revealed that patients requiring multiple Y-90 treatments (HR 2.9, p = 0.035) and patients who had previously failed systemic therapy with octreotide/chemotherapy (HR 4.4, p = 0.012) had worse survival. Grade 3 serologic toxicity was observed in 2 patients (5%; hyperbilirubinemia, elevated alkaline phosphatase) after treatment. Grade 3 non-serologic toxicities included abdominal pain (11%), fatigue (11%), nausea/vomiting (5%), ascites (5%), dyspnea (3%), diarrhea (3%), and peripheral edema (3%). No grade 4 or 5 toxicity was reported.

Conclusions

Y-90 radioembolization is a promising treatment option for inoperable NELM and is associated with low rates of grade ≥ 3 toxicity.